This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Study of Placebo or Bosentan to Treat Patients With Single Ventricle Physiology. (TEMPO)

This study has been completed.
Sponsor:
Collaborators:
Aarhus University Hospital
Bispebjerg Hospital
Actelion
Information provided by (Responsible Party):
Anders Hebert, Rigshospitalet, Denmark
ClinicalTrials.gov Identifier:
NCT01292551
First received: February 8, 2011
Last updated: April 18, 2013
Last verified: April 2013
  Purpose

The purpose of this study is to determine whether Bosentan is an effective and safe treatment to adolescent and adult (15 years and older) patients, born with one ventricle of the heart instead of two (single ventricle physiology) and who have undergone TCPC as a palliative surgical treatment. The aim of the TCPC operation is to use the one functioning ventricle to pump the blood flow to the body, while the blood to the lungs is received directly from the caval veins, and is thus a passive flow, without the aid of a ventricle to actively pump the blood through the pulmonary circulation. The resistance in the pulmonary circulation is therefore critical to these patients. These patients have markedly lower work capacity in bicycle test than the general public. Furthermore they have a high risk of developing complications e.g. loss of protein from the intestines.

Bosentan is a medication that lowers the resistance in the pulmonary circulation. It is routinely used for patients with pulmonary hypertension. Some studies have shown that drugs that lower the pulmonary resistance can increase exercise capacity significantly in patients with single ventricle physiology.

In this study 80 patients will receive either placebo or Bosentan for 14 weeks. Before and after the treatment, bicycle test along with blood samples, stool samples and quality of life interviews will be performed. Every four weeks during the study blood samples, physical exam and interviews will be performed to ensure the safety of the treatment.

The investigators expect to find a significant increase in work capacity after 14 weeks in the treatment group compared with the placebo group.

Moreover the investigators hope to find a decrease in intestinal protein loss and an improved quality of life.


Condition Intervention Phase
Hypoplastic Left Heart Syndrome Tricuspid Atresia Other Specified Congenital Anomalies of Heart Drug: Bosentan Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Treatment With Endothelin Antagonist to Tcpc Patients; a Multicenter, Randomized, Prospective Study Measuring Maximal O2 Uptake in Ergometer Bicycle Test

Resource links provided by NLM:


Further study details as provided by Anders Hebert, Rigshospitalet, Denmark:

Primary Outcome Measures:
  • Change from baseline in VO2max at 14 weeks [ Time Frame: Baseline and 14 weeks ]
    Maximal O2 uptake in ml/min/kg in ergometer bicycle test


Secondary Outcome Measures:
  • Change from baseline in blood samples at 14 weeks [ Time Frame: Baseline and 14 weeks ]
    blood samples measured: plasma CT pro endothelin-1, IgG, IgA, NT pro BNP, albumin, free protein

  • Change from baseline in SF36 questionnaire score at 14 weeks [ Time Frame: Baseline and 14 weeks ]
    SF36 quality of life interview

  • Change from baseline in feces alfa 1 antitrypsin at 14 weeks [ Time Frame: Baseline and 14 weeks ]
    Fecal alfa 1 antitrypsin in mg/g

  • Number of participants with adverse events [ Time Frame: 2, 6, 10 and 14 weeks after start of treatment ]
    general interview on adverse effects, and questions with special focus on typical adverse effects in Bosentan

  • Change from baseline in vital signs [ Time Frame: Baseline, 2, 6, 10 and 14 weeks ]
    Systemic bloodpressure in mmHg, Pulse in min-1, Oxygen saturation in percent

  • Change from baseline in control blood samples [ Time Frame: Baseline, 2, 6, 10 and 14 weeks ]
    Liver and renal biomarkers, Hb, PCV, trc and hCG for women

  • Change from baseline in cardiac output/pulmonary blood flow [ Time Frame: Baseline and 14 weeks ]
    CO measured by Stringer Wassermann method during ergometer bicycle test


Enrollment: 75
Study Start Date: February 2011
Study Completion Date: March 2013
Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Bosentan Drug: Bosentan
tablets Bosentan 62,5 mg x 2 daily for two weeks, then 125 mg x 2 daily for 12 weeks
Other Name: Bosentan: Tracleer
Placebo Comparator: Placebo Drug: Placebo
Placebo tablets 2 x daily for 2 weeks, then change to different placebo tablets to match Bosentan group, 2 x daily for 12 weeks

Detailed Description:

In the statistical analysis the investigators wish to analyse interactions between the primary endpoint and predefined subgroups in order to distinguish responders from non-responders to the treatment. The predefined subgroups are:

NT-proBNP > 100 (yes/no) Ventricular anatomy (RV/LV) CT-proEndothelin-1. In the latter, the investigators do not wish to predefine a specific value, due to limited experience with this analysis. We wish to use the data from the study to find a cut-off value, that is able to predict positive response to treatment.

  Eligibility

Ages Eligible for Study:   15 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • TCPC operated
  • Age > 15 years old
  • Clinical stability > 3 months, evaluated by investigator from clinical record
  • For women: Negative s-hCG and use of contraception

Exclusion Criteria:

  • Severe heart failure (NYHA-class IV)
  • Oxygen saturation < 85 % at rest
  • Pre-existing liver condition (transaminases 2x > reference)
  • Renal failure (creatinin > 150 mmol/l)
  • Obstruction of TCPC circulation
  • History of work induced severe arrhythmia
  • Systolic blood pressure below 80% of reference (BT < 88 mmHg)
  • Use of any of following drugs: Fluconazol, Ketoconazole, CiclosporinA, Lopinavir, Ritonavir, Rifampicin, Carbamazepin and Phenytoin
  • Significant extra-cardiac condition e.g. neurological impairment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01292551

Locations
Denmark
Aarhus University Hospital
Aarhus, Denmark, 8200
Rigshospitalet
Copenhagen, Denmark, 2100
Sweden
Lund University Hospital
Lund, Sweden
Karolinska Institutet
Stockholm, Sweden
Sponsors and Collaborators
Rigshospitalet, Denmark
Aarhus University Hospital
Bispebjerg Hospital
Actelion
Investigators
Study Director: Lars Sondergaard, DMSc Rigshospitalet, Denmark
Principal Investigator: Anders H Hebert, MD Rigshospitalet, Denmark
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Anders Hebert, M.D., Rigshospitalet, Denmark
ClinicalTrials.gov Identifier: NCT01292551     History of Changes
Other Study ID Numbers: TEMPO study
2010-022389-28 ( EudraCT Number )
Study First Received: February 8, 2011
Last Updated: April 18, 2013

Keywords provided by Anders Hebert, Rigshospitalet, Denmark:
single ventricle physiology
Fontan procedure

Additional relevant MeSH terms:
Hypoplastic Left Heart Syndrome
Congenital Abnormalities
Tricuspid Atresia
Heart Defects, Congenital
Cardiovascular Abnormalities
Cardiovascular Diseases
Heart Diseases
Heart Valve Diseases
Bosentan
Antihypertensive Agents
Endothelin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on July 25, 2017